Device Devices

Excluder Conformable Aaa Endoprosthesis With Active Control

Payments companies reported to CMS as associated with Excluder Conformable Aaa Endoprosthesis With Active Control. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$1.0Massociated payments (2023-2025)
2,652clinicians with associated payments
1company reporting

By year

2023 $412K
2024 $296K
2025 $327K

Payments reported as associated with Excluder Conformable Aaa Endoprosthesis With Active Control, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Vascular Surgery $834K
Surgery $48K
Thoracic Surgery (Cardiothoracic Vascular Surgery) $42K
Cardiovascular Disease $28K
Diagnostic Radiology $16K
Vascular & Interventional Radiology $10K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Excluder Conformable Aaa Endoprosthesis With Active Control

These are the largest totals companies reported as associated with Excluder Conformable Aaa Endoprosthesis With Active Control. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Ross Milner Chicago, IL Vascular Surgery $76,639.92
Sukgu Han Los Angeles, CA Vascular Surgery $47,634.37
Robert Rhee Brooklyn, NY Vascular Surgery $38,649.38
Trissa Babrowski Chicago, IL Vascular Surgery $38,098.21
Jason Lee Palo Alto, CA Vascular Surgery $37,649.72
Nathan Liang Pittsburgh, PA Vascular Surgery $29,059.95
Gregory Magee Los Angeles, CA Vascular Surgery $28,081.58
Gustavo Oderich Houston, TX Vascular Surgery $24,535.92
Sharon Kiang Los Angeles, CA Vascular Surgery $23,609.90
Sara Zettervall Seattle, WA Vascular Surgery $22,824.99

Prescribed Excluder Conformable Aaa Endoprosthesis With Active Control?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.